Chronix closes in on $1.7M for chronic disease diagnosis
Chronix Biomedical, maker of various products used to detect and diagnose chronic diseases, has almost completed its $1.7 million round of equity, according to a filing with the SEC. Based in San Jose, Calif., the company is backed by Pentagram Partners and PrairieGold Venture Partners.
Diagnostics firm Chronix busts out of stealth, looks for cash
Chronix Biomedical, a diagnostic test development company that has operated mostly in secret since its 2000 inception, has finally come out of its shell — publishing information on its product in three academic journals and announcing its push for commercialization. To fuel the latter, it has already secured $845,000 in a third round of venture funding but hopes to rack up at least $2 or $3 million before the close of the round, VentureWire reports.
The… Continue Reading
The termite’s blessing: ZeaChem finds more support
Poor termites. They’ll have no part in the ZeaChem facilities that may someday pump out millions of gallons of cellulosic ethanol, even though it’s the humble bug’s legacy that allowed it all to happen. Lakewood, Colo.-based ZeaChem has raised $34 million more for its process, the most important step of which uses a microorganism from the termite’s digestive tract to break down wood and similar materials into fuel.
ZeaChem chief executive Jim Imbler thinks he’s starting… Continue Reading
Stealth startup Chronix Biomedical raises $2.27M
San Jose, Calif.-based Chronix is working on means to detect and monitor chronic diseases. It has raised a small $2.27 million second round from Pentagram Partners LP, PrairieGold Venture Partners and individual investors, VentureWire reports.
Life sciences briefing: Friday, Oct. 12, 2007
Featured companies: CeraPedics, Lab21, Incisive Surgical, Orasi Medical, Transoma Medcal, ZyGem
(UPDATED: Expanded items on Transoma, Lab21 and Orasi.)
Medical-device maker Transoma files for $75M IPO — St. Paul, Minn.-based Transoma Medical, a developer of implantable wireless diagnostic sensors, filed to raise $75 million in an initial offering. The company is currently focused on the markets for heart patients and general biomedical research.
Transoma received FDA “clearance” for its first product on Oct. 1. That device, called the Sleuth ECG… Continue Reading